GSK hands off dermatitis, psoriasis candidate to Dermavant
The Dermavant Sciences dermatology subsidiary of Roivant Sciences GmbH (Basel, Switzerland) will shell out £150 million ($200 million) up front to GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to receive global rights to atopic dermatitis and psoriasis candidate tapinarof (GSK2894512, WBI-1001). The deal excludes China and is expected to close this half....